LEO Pharma's Enstilar gives positive Phase III data in psoriasis

Danish pharma company LEO Pharma has announced new data showing Enstilar(calcipotriol/betamethasone dipropionate)  in the treatment of psoriasis vulgaris provides rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis.

The data comes from PSO-FAST, a large, Phase III, double-blind trial including 426 psoriasis patients in the USA. Patients were split into two groups, where 323 received Enstilar and 103 received placebo in the form of the aerosol foam vehicle alone. Results showed that 37% of patients using Enstilar achieved improvements in itching after three days and 84% achieved improvements by week four. They similarly experienced improvements in itch-related sleep loss, with 36% improving after three days and 71% improving by week four.

Kim Kjøller, senior vice president of global development at LEO Pharma, said: “We are pleased with the results of the PSO-FAST trial and believe these data further highlight the value Enstilar may provide to patients living with psoriasis. Improving the lives of patients living with skin diseases is our number one priority and we look forward to continuing to work with regulatory authorities to obtain approval and make Enstilar available to patients worldwide.”